tldrdailynews.com logo

CG Oncology's Successful IPO Sets Positive Tone for Biotech Public Offerings

1 min read
Source: Endpoints News
CG Oncology's Successful IPO Sets Positive Tone for Biotech Public Offerings
Photo: Endpoints News
TL;DR

CG Oncology's $380 million IPO debut could serve as a barometer for the future of public offerings in 2023, as the biotech industry sees a potential increase in IPO activity following a significant decrease in the past two years. Industry insiders caution against drawing conclusions based on one company, but with at least five other biotechs poised to follow suit, more data points will soon be available.

Topics:businessfinance#biotechs#cg-oncology#finance#ipo#public-offerings#stock-market
Share this article
  1. Is CG Oncology's IPO a benchmark for a better year in public offerings?  Endpoints News
  2. Bladder cancer biotech CG Oncology raises $380 million in IPO  Axios
  3. CG Oncology, Inc. Rings the Opening Bell  Nasdaq
  4. CG Oncology Shares Rise 63% in Debut  MarketWatch
  5. In first biotech IPO of the year, CG Oncology overshoots estimates by bringing in $380M  FierceBiotech

Want the full story? Read the original reporting

Read on Endpoints News